Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
nicotinic acid or nicotinoyl alcohol derivatives	1919	65141-46-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nicorandil perisalol sigmart	A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase. Molecular weight: 211.18 Formula: C8H9N3O4 CLOGP: 0.54 LIPINSKI: 0 HAC: 7 HDO: 1 TPSA: 97.04 ALOGS: -2.25 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nicorandil
perisalol
sigmart

A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.

Molecular weight: 211.18
Formula: C8H9N3O4
CLOGP: 0.54
LIPINSKI: 0
HAC: 7
HDO: 1
TPSA: 97.04
ALOGS: -2.25
ROTB: 5

Drug dosage:

Dose	Unit	Route
40	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	4.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4.06 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	75 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.76 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.60 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,MAP3K21,MAP3K7,MAPK1,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ZAP70	55
kinase-selectivity-class	AXL,BRAF,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,MAP2K6,MAPK7,PRKDC,SIK2,STK33,TEK,TTK	15
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1984	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	85.54	25.95	86	3833	320301	90304227
Cardiac failure	65.84	25.95	47	3872	109449	90515079
Upper gastrointestinal haemorrhage	53.49	25.95	24	3895	22952	90601576
Drug interaction	50.68	25.95	61	3858	276392	90348136
Acute coronary syndrome	44.59	25.95	17	3902	10796	90613732
Fixed eruption	43.99	25.95	11	3908	1719	90622809
Hyponatraemia	43.34	25.95	40	3879	133498	90491030
Bradycardia	41.41	25.95	32	3887	83815	90540713
Haemorrhage intracranial	39.03	25.95	17	3902	15145	90609383
Hypotension	38.47	25.95	58	3861	325339	90299189
Rhabdomyolysis	35.45	25.95	24	3895	51232	90573296
Renal impairment	35.01	25.95	32	3887	105389	90519139
Brain stem stroke	34.74	25.95	7	3912	411	90624117
Hypomagnesaemia	32.88	25.95	20	3899	35568	90588960
Cerebral infarction	32.70	25.95	18	3901	26578	90597950
Hyperkalaemia	30.35	25.95	24	3895	64940	90559588
Angina pectoris	28.67	25.95	19	3900	39141	90585387
Melaena	28.21	25.95	18	3901	34779	90589749
Large intestinal ulcer	26.94	25.95	9	3910	3908	90620620
Eyelid ptosis	26.15	25.95	11	3908	8995	90615533

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Postictal paralysis	57.05	19.31	13	6740	364	42614218
Interstitial lung disease	56.83	19.31	66	6687	78396	42536186
Cardiac failure	52.32	19.31	74	6679	106782	42507800
Melaena	50.89	19.31	45	6708	38701	42575881
Angina pectoris	46.82	19.31	40	6713	32856	42581726
Acute kidney injury	40.70	19.31	139	6614	367198	42247384
Cerebral infarction	38.55	19.31	35	6718	31134	42583448
Drug interaction	35.85	19.31	108	6645	266891	42347691
Intraventricular haemorrhage	33.53	19.31	15	6738	3869	42610713
Hepatic function abnormal	33.39	19.31	41	6712	51526	42563056
Lactic acidosis	32.61	19.31	38	6715	45223	42569359
Acute myocardial infarction	32.53	19.31	43	6710	58122	42556460
Altered state of consciousness	28.85	19.31	29	6724	29230	42585352
Haemoptysis	28.75	19.31	36	6717	46131	42568451
Prinzmetal angina	28.62	19.31	10	6743	1347	42613235
Hypotension	27.15	19.31	96	6657	257535	42357047
Muscle haemorrhage	26.54	19.31	13	6740	4112	42610470
Pneumonia aspiration	26.44	19.31	36	6717	50042	42564540
Drug ineffective	26.41	19.31	37	6716	630160	41984422
Chest pain	26.27	19.31	64	6689	139466	42475116
Hypomagnesaemia	25.85	19.31	27	6726	28461	42586121
Pericardial haemorrhage	25.24	19.31	12	6741	3557	42611025
Electrocardiogram QT prolonged	24.60	19.31	34	6719	47911	42566671
Coronary artery restenosis	24.18	19.31	8	6745	914	42613668
Cardiac failure chronic	23.19	19.31	16	6737	9585	42604997
Gastrointestinal haemorrhage	23.02	19.31	49	6704	97677	42516905
Prerenal failure	22.95	19.31	10	6743	2423	42612159
Eosinophilia	22.66	19.31	27	6726	32872	42581710
Bradycardia	22.65	19.31	45	6708	85439	42529143
Cardiac failure acute	22.34	19.31	18	6735	13615	42600967
Malaise	22.27	19.31	79	6674	212077	42402505
Haemorrhage subcutaneous	22.15	19.31	10	6743	2636	42611946
Hypovitaminosis	21.33	19.31	7	6746	779	42613803
Photosensitivity reaction	21.30	19.31	17	6736	12685	42601897
Muscle contractions involuntary	21.29	19.31	9	6744	2025	42612557
Renal impairment	21.20	19.31	51	6702	110177	42504405
Pemphigoid	20.64	19.31	16	6737	11451	42603131
Cardiorenal syndrome	20.46	19.31	7	6746	886	42613696
Ileal ulcer	20.07	19.31	7	6746	937	42613645
Gastric ulcer	19.67	19.31	19	6734	18243	42596339
Drug-induced liver injury	19.42	19.31	27	6726	38246	42576336
Inappropriate antidiuretic hormone secretion	19.32	19.31	18	6735	16523	42598059

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	123.54	18.55	222	10624	635208	109943245
Cardiac failure	107.28	18.55	111	10735	187515	110390938
Drug interaction	96.08	18.55	174	10672	500009	110078444
Melaena	82.44	18.55	62	10784	68695	110509758
Interstitial lung disease	77.02	18.55	81	10765	139253	110439200
Angina pectoris	76.52	18.55	57	10789	62238	110516215
Cerebral infarction	76.43	18.55	53	10793	51785	110526668
Upper gastrointestinal haemorrhage	71.01	18.55	50	10796	50046	110528407
Hepatic function abnormal	62.42	18.55	59	10787	89236	110489217
Bradycardia	61.48	18.55	76	10770	155441	110423012
Hyponatraemia	61.07	18.55	90	10756	217563	110360890
Acute myocardial infarction	59.80	18.55	56	10790	83721	110494732
Acute coronary syndrome	57.69	18.55	33	10813	23079	110555374
Renal impairment	57.35	18.55	81	10765	188364	110390089
Postictal paralysis	56.79	18.55	13	10833	608	110577845
Hypotension	56.19	18.55	144	10702	523705	110054748
Hypomagnesaemia	54.30	18.55	46	10800	60324	110518129
Pneumonia aspiration	51.74	18.55	51	10795	81182	110497271
Gastrointestinal haemorrhage	50.14	18.55	71	10775	165447	110413006
Lactic acidosis	47.81	18.55	52	10794	92759	110485694
Prinzmetal angina	44.22	18.55	14	10832	2255	110576198
Drug ineffective	42.78	18.55	52	10794	1520488	109057965
Electrocardiogram QT prolonged	42.64	18.55	53	10793	108907	110469546
Cerebral haemorrhage	41.76	18.55	41	10805	64927	110513526
Gastric ulcer	41.37	18.55	33	10813	39794	110538659
Ischaemic stroke	40.34	18.55	33	10813	41230	110537223
Haemorrhage intracranial	38.93	18.55	28	10818	28941	110549512
Blood pressure decreased	37.28	18.55	51	10795	115040	110463413
Rhabdomyolysis	36.97	18.55	52	10794	120349	110458104
Pemphigoid	35.91	18.55	23	10823	19684	110558769
Intraventricular haemorrhage	35.41	18.55	15	10831	5492	110572961
Haemoptysis	35.05	18.55	39	10807	71315	110507138
Hyperkalaemia	34.99	18.55	54	10792	135742	110442711
Ventricular fibrillation	34.14	18.55	30	10816	41283	110537170
Hypoglycaemia	33.96	18.55	49	10797	116055	110462398
Fall	33.31	18.55	132	10714	603350	109975103
Altered state of consciousness	32.70	18.55	34	10812	57592	110520861
Cardiac failure chronic	32.55	18.55	19	10827	13792	110564661
Pain	29.69	18.55	30	10816	954925	109623528
Angina unstable	29.50	18.55	19	10827	16413	110562040
Drug intolerance	29.17	18.55	3	10843	406509	110171944
Muscle haemorrhage	29.16	18.55	14	10832	6855	110571598
Hypokalaemia	28.18	18.55	58	10788	182390	110396063
Arthralgia	27.19	18.55	22	10824	779610	109798843
Orthostatic hypotension	27.16	18.55	33	10813	66216	110512237
Infusion related reaction	26.87	18.55	3	10843	381159	110197294
Pericardial haemorrhage	26.38	18.55	12	10834	5205	110573248
Pulmonary alveolar haemorrhage	25.99	18.55	19	10827	20131	110558322
Coronary artery restenosis	25.93	18.55	8	10838	1184	110577269
Anaemia	25.74	18.55	114	10732	546972	110031481
Weight increased	25.68	18.55	5	10841	419639	110158814
Fixed eruption	25.47	18.55	11	10835	4221	110574232
Lip swelling	25.40	18.55	28	10818	50639	110527814
Myocardial ischaemia	25.37	18.55	21	10825	26663	110551790
Cardiac failure acute	25.11	18.55	20	10826	24058	110554395
Kounis syndrome	24.92	18.55	12	10834	5913	110572540
Prerenal failure	24.92	18.55	11	10835	4448	110574005
Brain stem stroke	24.69	18.55	7	10839	774	110577679
Disseminated intravascular coagulation	24.58	18.55	25	10821	41261	110537192
Duodenal ulcer	24.27	18.55	18	10828	19496	110558957
Immune thrombocytopenia	24.13	18.55	19	10827	22475	110555978
Inappropriate antidiuretic hormone secretion	22.94	18.55	22	10824	33829	110544624
Haemorrhage subcutaneous	22.64	18.55	11	10835	5528	110572925
Eosinophilia	22.36	18.55	28	10818	57908	110520545
Circulatory collapse	21.97	18.55	24	10822	42969	110535484
International normalised ratio increased	21.63	18.55	34	10812	86738	110491715
Blood creatine phosphokinase increased	21.59	18.55	31	10815	73046	110505407
Nasopharyngitis	21.55	18.55	6	10840	394355	110184098
Abdominal discomfort	21.50	18.55	6	10840	393852	110184601
Dehydration	21.27	18.55	68	10778	279443	110299010
Chest pain	21.27	18.55	83	10763	376292	110202161
Pancytopenia	20.73	18.55	56	10790	209557	110368896
Myocardial infarction	20.72	18.55	53	10793	192030	110386423
Hypovitaminosis	20.37	18.55	7	10839	1453	110577000
Coagulation factor deficiency	20.20	18.55	5	10841	327	110578126
Arterial injury	19.86	18.55	6	10840	828	110577625
Labelled drug-drug interaction medication error	19.77	18.55	19	10827	29283	110549170
Ileus paralytic	19.67	18.55	13	10833	11724	110566729
Marasmus	19.37	18.55	7	10839	1684	110576769
Large intestinal ulcer	19.30	18.55	10	10836	5751	110572702
Shock	19.26	18.55	25	10821	53563	110524890
Muscle contractions involuntary	18.69	18.55	9	10837	4435	110574018
Head injury	18.57	18.55	22	10824	42995	110535458

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01DX16	CARDIOVASCULAR SYSTEM CARDIAC THERAPY VASODILATORS USED IN CARDIAC DISEASES Other vasodilators used in cardiac diseases
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D014665	Vasodilator Agents
MeSH PA	D014803	Vitamin B Complex
MeSH PA	D014815	Vitamins
MeSH PA	D018977	Micronutrients
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35620	vasodilator agent
CHEBI has role	CHEBI:79085	potassium channel opener

Related Drugs by ATC class:

C01DX Other vasodilators used in cardiac diseases 18 drugs

benziodarone carbocromen cinepazet cloridarol dilazep efloxate etafenone heptaminol hexobendine imolamine itramin tosilate linsidomine show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Angina pectoris	indication	194828000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.97	acidic
pKa2	3.07	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
ATP-sensitive inward rectifier potassium channel 11	Ion channel	Q14654	KCJ11_HUMAN	IC50	5.89	WOMBAT-PK
ATP-sensitive inward rectifier potassium channel 1	Ion channel	P48048	KCNJ1_HUMAN	IC50	5.95	WOMBAT-PK
Atrial natriuretic peptide receptor 1	Enzyme	P16066	ANPRA_HUMAN	EC50	7.20	WOMBAT-PK

External reference:

ID	Source
N0000167327	NUI
D01810	KEGG_DRUG
C0068700	UMLSCUI
CHEBI:31905	CHEBI
CHEMBL284906	ChEMBL_ID
DB09220	DRUGBANK_ID
D020108	MESH_DESCRIPTOR_UI
47528	PUBCHEM_CID
2411	IUPHAR_LIGAND_ID
4933	INN_ID
260456HAM0	UNII
31748	RXNORM
005831	NDDF
319304004	SNOMEDCT_US
395809002	SNOMEDCT_US
260456HAM0	INXIGHT DRUGS

Pharmaceutical products:

None

Ask DrugCentral

Try a sample question

nicorandil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: